Amgen Inc
Pagina dedicata companiei Amgen Inc listata cu simbolul US.AMGN
Descriere companie[edit | ]
Amgen Inc. (www.amgen.com) is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine). It focuses on human therapeutics for the treatment of serious illness in the areas of oncology/hematology, cardiovascular disease and neuroscience. Its product candidates in Phase III include Erenumab for episodic migraine, Aranesp for myelodysplastic syndromes, BLINCYTO for acute lymphoblastic leukemia and IMLYGIC for metastatic melanoma.
Ultimele stiri despre Amgen Inc (US.AMGN)[edit | ]
- Amgen anunta achizitia anului in sectorul medical
- Importurile, din ce in ce mai atragatoare - 13 decembrie 2022
- Jim Cramer picks 7 Dow stocks that investors should consider owning - 06 iulie 2022
- Amgen anunta achizitia anului in sectorul medical - 14 decembrie 2022
- Importurile, din ce in ce mai atragatoare
- Amgen Inc